12 unchanged sentences
The following performance graph and related information shall not be deemed to be “soliciting material” or to be “filed” with the SEC for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section, nor shall such information be incorporated by reference into any future filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except to the extent that we specifically incorporate it by reference into such filing.
−Removed: The following graph compares the performance of our common stock to The Nasdaq Composite Index and to The Nasdaq Biotechnology Index from February 3, 2016 (the first date on which shares of our common stock were publicly traded) through December 31, 2020.
−Removed: The comparison assumes $100 was invested after the market closed on February 3, 2016 in our common stock and in each of the foregoing indices, and it assumes reinvestment of dividends, if any.
+Added: The following graph compares the performance of our common stock to The Nasdaq Composite Index and to The Nasdaq Biotechnology Index from December 30, 2016 through December 31, 2021.
+Added: The comparison assumes $100 was invested after the market closed on December 30, 2016 in our common stock and in each of the foregoing indices, and it assumes reinvestment of dividends, if any.
The stock price performance included in this graph is not necessarily indicative of future stock price performance.
Recent Sales of Unregistered Securities
−Removed: On November 9, 2020, we granted our Chief Medical Officer an option to purchase 120,000 shares of our common stock and a restricted stock unit award of 20,000 shares as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
−Removed: No underwriters were involved in the foregoing issuance of securities.
−Removed: The securities were issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, relating to transactions by an issuer not involving any public offering.
−Removed: The recipient either received adequate information about us or had access, through other relationships, to such information.
−Removed: The stock option is scheduled to become exercisable as to 25% of the shares underlying the option on the first anniversary of the date of grant, and as to an additional 2.0833% of the shares underlying the option at the end of each successive month following such date, subject to the recipient’s continued service.
−Removed: The option has an exercise price of $30.41 per share.
−Removed: The restricted stock unit award is scheduled to vest as to one-fourth of the shares on each anniversary of the date of grant until the fourth anniversary of the date of grant, subject to the recipient’s continued service.
−Removed: On January 22, 2021, we issued an aggregate of 303,599 shares of common stock to The Broad Institute, Inc.
−Removed: (“Broad”) in satisfaction of payment obligations in an aggregate amount of $27.5 million to Broad under the Cpf1 License Agreement and the Sponsored Research Agreement.
−Removed: No underwriters were involved in the foregoing issuance of securities.
−Removed: The securities were issued pursuant to Section 4(a)(2) under the Securities Act, relating to transactions by an issuer not involving any public offering.
−Removed: Prior to receiving the shares, Broad represented to us that it was acquiring the shares for its own account for investment purposes, that it had received from us and our management all of the information that it considered appropriate to evaluate whether to accept the shares, that it was capable of evaluating and understanding the risks of the investment, and that it was an accredited investor as such term is defined in Rule 501 of Regulation D promulgated under the Securities Act.
Purchases of Equity Securities by the Issuer and Affiliates Purchasers
Neither we nor any affiliated purchaser or anyone acting on behalf of us or an affiliated purchaser made any purchases of shares of our common stock during the fourth quarter of 2021.
−Removed: Selected Consolidated Financial Data.
−Removed: You should read the following selected consolidated financial data together with our consolidated financial statements and accompanying notes appearing elsewhere in this Annual Report on Form 10-K and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of this Annual Report on Form 10-K.
−Removed: The following selected consolidated financial data are derived from our audited consolidated financial statements.
−Removed: Our historical results for any prior period are not necessarily indicative of the results that may be expected in any future period.
−Removed: Our consolidated statements of operations are summarized as follows (in thousands, except share and per share amounts):
−Removed: Consolidated Statements of Operations Data:
−Removed: Collaboration revenue
−Removed: Operating expenses:
−Removed: Research and development
−Removed: General and administrative
−Removed: Total operating expenses
−Removed: Operating loss
−Removed: Other income (expense), net
−Removed: Interest income, net
−Removed: Total other income, net
−Removed: Net loss and comprehensive loss
−Removed: Reconciliation of net loss to net loss attributable to common stockholders:
−Removed: Accretion of redeemable convertible preferred stock to redemption value (1)
−Removed: Net loss attributable to common stockholders (1)
−Removed: Net loss per share attributable to common stockholders, basic and diluted
−Removed: Weighted-average common shares outstanding, basic and diluted (1)
−Removed: (1) See Note 15 to our consolidated financial statements for further details on the calculation of net loss per share, basic and diluted, attributable to common stockholders and the weighted-average number of shares used in the computation of the per share amounts.
−Removed: Our consolidated balance sheets are summarized as follows (in thousands, except share and per share amounts):
−Removed: Consolidated Balance Sheet Data:
−Removed: Cash, cash equivalents, and marketable securities
−Removed: Working capital
−Removed: Deferred revenue, net of current portion
−Removed: Construction financing lease obligation, net of current portion
−Removed: Total stockholders’ equity
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.